Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Gains from Sales and Divestitures (2017 - 2025)

Harvard Bioscience (HBIO) has disclosed Gains from Sales and Divestitures for 9 consecutive years, with $442448.0 as the latest value for Q2 2025.

  • Quarterly Gains from Sales and Divestitures rose 194.21% to $442448.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $442448.0 through Jun 2025, up 194.21% year-over-year, with the annual reading at $717119.0 for FY2024, 126.79% up from the prior year.
  • Gains from Sales and Divestitures for Q2 2025 was $442448.0 at Harvard Bioscience, up from $247097.0 in the prior quarter.
  • The five-year high for Gains from Sales and Divestitures was $1.2 million in Q4 2021, with the low at $33979.0 in Q1 2024.
  • Average Gains from Sales and Divestitures over 5 years is $365998.0, with a median of $316210.0 recorded in 2023.
  • The sharpest move saw Gains from Sales and Divestitures plummeted 72.82% in 2024, then soared 627.21% in 2025.
  • Over 5 years, Gains from Sales and Divestitures stood at $1.2 million in 2021, then plummeted by 65.63% to $401308.0 in 2022, then fell by 21.21% to $316210.0 in 2023, then skyrocketed by 126.79% to $717119.0 in 2024, then tumbled by 38.3% to $442448.0 in 2025.
  • According to Business Quant data, Gains from Sales and Divestitures over the past three periods came in at $442448.0, $247097.0, and $717119.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.